Compare Medpace Holdings Inc (MEDP) vs Walmart Stores Inc (WMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Medpace Holdings Inc vs Walmart Stores Inc — how do they compare? Medpace Holdings Inc trades at $597.39 (market cap $16.90B), while Walmart Stores Inc trades at $116.05 (market cap $901.33B). The key difference: Walmart Stores Inc is far larger — about 53.3× Medpace Holdings Inc's market cap, and Walmart Stores Inc pays a 0.87% dividend while Medpace Holdings Inc pays none. Which is the better fit depends on your goals.
| MEDP | WMT | |
|---|---|---|
Market Cap | $16.90B | $901.33B |
Sector | Technology | Consumer Staples |
52-Week High | $620.59 | $134.20 |
52-Week Low | $393.42 | $96.05 |
Enterprise Value | $16.52B | $964.78B |
Volume | — | 5,675,288 |
Dividend Yield | — | 0.87% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MEDP trades at $596.98, down 0.9% on the day but near its 52-week highs. The stock shows strong technical momentum with bullish moving averages and recent golden cross formation. Fundamentally, the company delivered three consecutive quarterly earnings beats with Q2 2026 EPS of $4.25 beating expectations of $3.98. Revenue growth remains robust at 17.2% year-over-year in Q2 2026, supported by record net bookings and a $3.0 billion backlog.
MEDP presents a growth story with strong fundamentals but trades at premium valuations (P/E 35.58, P/S 6.27). The primary investment opportunity lies in continued execution on record bookings and backlog conversion. Key risks include the ongoing shareholder litigation investigation and potential valuation compression if growth moderates. Analyst consensus targets $599.57 with 21% buy ratings, suggesting limited near-term upside from current levels.
Walmart (WMT) trades at $112.66, up 0.72% with strong fundamental performance including three consecutive quarterly EPS beats and robust revenue growth to $681B in 2025. The stock shows neutral technical signals with RSI at 62.52, while analyst consensus remains strongly bullish with a $142 price target. Recent developments include AI tool innovations and expanded delivery services positioning the company for continued market leadership.
Walmart presents a compelling investment case with solid fundamentals and analyst support, though valuation multiples appear elevated. Key opportunities include sustained revenue growth and operational efficiency gains, while risks involve competitive pressures from Amazon and potential margin compression. The stock offers 26% upside to consensus targets but requires monitoring of execution against high expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →About Walmart Stores Inc
Walmart Inc. operates discount stores, supercenters, and neighborhood markets. The Company offers merchandise such as apparel, house wares, small appliances, electronics, musical instruments, books, home improvement, shoes, jewelry, toddler, games, household essentials, pets, pharmaceutical products, party supplies, and automotive tools. Walmart serves customers worldwide.
Read more on WMT →
